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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMMethods: We used claims data from the Truven Health MarketScan Commercial and
Medicare Supplemental Databases to identify adults with incident PCI (index event)
from 2008-2011. We excluded patients who had less than 12 months of continuous
medical and pharmacy beneﬁts before or after the index procedure; patients were
followed for 12 - 24 months after their index PCI. Baseline characteristics were
deﬁned in the 12-month pre-index period. Clinical outcomes were deﬁned as an
inpatient claim with a principal diagnosis of angina, chest pain, or acute coronary
syndrome (ACS); new angina or chest pain were also deﬁned by presence of an
outpatient claim with an accompanying stress test or repeat PCI. Repeat PCI was
deﬁned as a PCI occurring at least 30 days post-index; PCIs < 30 days post-index
were considered staged procedures.
Results: A total of 51,710 patients met the study criteria (mean age 61.8
[SD¼11.3], 72.4% male). Of these, 33,197 (64.2%) had 24 months of follow-up.
Cumulative incidence of post-index angina or chest pain was 24.8% in the ﬁrst year
and increased to 33.9% by end of year 2. At two years, 4.1% of patients had had an
ACS event. Repeat PCI occurred in 10.8% of patients by one year and 15.1% by
two years.
Conclusions: Persistent or recurrent angina and chest pain remains a signiﬁcant
clinical challenge. Recurrent events, including angina, chest pain, and repeat-PCI,
occurred in approximately one-quarter of patients in the ﬁrst year post-procedure
and increased in the second year of post-procedure follow-up, indicating substantial
burden to patients and payers. Strategies that reduce these adverse events are
needed.
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Background: Previous studies have shown gender impact on clinical outcomes in
patients presenting with coronary artery disease. However, exact role of gender impact
in these studies still have not been fully investigated.
Methods: Gender differences were evaluated in the clinical outcomes of 9,674
patients with coronary artery disease from a large, 55 multicenter, contemporary
percutaneous coronary intervention (PCI) registry enrolled between April 2008
and November 2011 in Korea; the IRIS DES registry. 3,097 women and 6,577
men were followed-up for more than 2 year. The primary end point was rates of
major adverse cardiovascular events (MACE), deﬁned as cardiac death,
myocardial infarction (MI), and target vessel revascularization (TVR) at 2 year
follow-up.
Results: At baseline, women, as compared with men, were older, more frequently had
diabetes, hypertension, and previous congestive heart failure, less frequently had
smoking habits, family history of coronary artery disease, previous MI, and previous
PCI, and had a smaller average stent diameter of the target vessel. The unadjusted
rates of death (3.5% vs 3.3%, P¼0.578), MACE (6.0% vs 6.0%, p¼0.946), and TVR
(1.8% vs1.6%, p¼0.573) were comparable for women and men. MI (1.1% vs 0.9%,
p¼0.494) were similar between men and women. After adjustment for baseline
characteristics in the multivariable analysis, women and men had a similar risk of
MACE rates at 2 year follow up.
Conclusions: Although women had worse baseline characteristics, no differences
in MACE and death were observed between men and women undergoing PCI
with DES.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AngioplasTCT-104
Does Direct Stenting with Drug-eluting Stents Improve Outcome? A Systematic
Review with Meta-Analysis of 10,513 Patients
Marco A. Magalhaes1, Sa’ar Minha1, Ricardo O. Escarcega2, Michael J. Lipinski2,
Nevin C. Baker1, Thibault Lhermusier2, lakshmana Pendyala3, Hideaki Ota4,
Wenjie Tian2, Michelle Deville5, Petros Okubagzi3, Fang Chen6, Rebecca Torguson7,
William O. Suddath6, Itsik Ben Dor3, Augusto Pichard8, Lowell F. Satler3,
Ron Waksman2
1MedStar Washington Hospital Center, Washington, DC, 2Medstar Washington
Hospital Center, Washington, DC, 3Washington Hospital Center, Washington, DC,
4Medstar Washington Hospital Center, Washington , DC, 5Washington Hospital
Center, NW, Washington, DC, DC, 6Medstat Washington Hospital Center,
Washington, DC, 7Washington Hospital center, Washington, DC, 8washsington
hospital center, Washington, United States
Background: Although direct stenting with drug-eluting stents (DES) has been
adopted as standard of care, its safety and effectiveness in comparison to the formally
recommended conventional pre-dilatation strategy remains not well established.
Methods: Medline/Pubmed, Cochrane Library, and EMBASE were searched from
2001 to 2014 for studies contrasting Direct DES with conventional pre-dilatation DES
implantation. The primary outcome was major adverse cardiovascular events
(MACE). Secondary outcomes included all-cause death or myocardial infarction (MI),
and target lesion revascularization (TLR). Summarized estimates were obtained using
a random-effects model. Heterogeneity across the studies was assessed through I2.
Results: Overall, 546 potentially relevant citations were screened with 407 excluded
from the title. The remaining 139 abstracts were analyzed resulting in six studies that
met the inclusion criteria enrolling a total of 10,513 participants. Of those, 3909 (37%)
and 6604 (63%) underwent direct DES or pre-dilatation followed by DES implanta-
tion, respectively. Direct DES reduced the likelihood of MACE (odds ratio [OR]: 0.80
95% conﬁdence interval [CI]: 0.70-0.92) with no evidence of heterogeneity of effect
(I2¼ 0%). Additionally, in comparison with pre-dilatation, Direct DES was also
associated with reduced rates of death or MI (OR: 0.74 95% CI [0.60-0.91], I2¼ 0%),
and TLR (OR: 0.60 95% CI [0.41-0.88],I2¼ 14%)(Figure).
Conclusions: Our ﬁndings support the strategy of direct DES for selected patient and
lesion population.TCT-105
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Background: In an effort to harmonize regulatory approval in Japan and Europe we
conducted large, multicentre, randomized CENTURY II clinical trial to assess per-
formance of new sirolimus-eluting stent with bioresorbable polymer (Ultimas-
ter,Terumo Corporation, Tokyo) fully designed and manufactured in Japan. We
compared Ultimaster with Xience DES. The study also addressed regional differences
in percutaneous intervention practice.
Methods: The CENTURY II enrolled 1123 patients in 58 hospitals in Europe, Japan
and Korea. The randomization was stratiﬁed for DES indications in Japan and in this
cohort 724 patients were enrolled. The principal difference from the total population
was exclusion of patients with acute myocardial infarction, left main disease, 3 vessels
disease, ostial lesion, saphenous vein graft, and in-stent restenosis. Primary endpointty Overview and Outcomes B31
